Drug Companies Seek Trademarks At Early Stage, Survey Finds
The overwhelming majority of the companies surveyed develops the generic and trademark names--92% and 84% respectively--by or during Phase II of clinical trials, according to a new benchmark study by consulting firm Best Practices, LLC.
As many as 40% of companies use the trademark before using the generic name, reflecting a growing trend to entrench the trademark...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login